NEW YORK, Jan. 5, 2016 /PRNewswire/ -- Are prescribing constraints costing your brand market share?
Doctors can't always prescribe the asthma/COPD drugs they want to prescribe. The reason: market barriers—things like pricing, reimbursement, guidelines, patient preferences, and more.
Barriers like these are a threat to leading brands' market share. But they also offer opportunities for brands to take market share from competitors.
FirstView's Market Access Impact in Asthma/COPD report takes an in-depth look at the way barriers affect asthma/COPD prescribing, and reveals which brands are winning and losing market share because of it. See what brands are included in this report
Not your market? Click here to see the EU5 Edition
Answering key questions
Packed with physician insight into seven of the leading asthma/COPD brands, Market Access Impact in Asthma/COPD answers key questions like:
Advair: with nearly equal barrier-related gains and losses, what can Advair do to tip the scales in its favour?
Arcapta: would eliminating market barriers move Arcapta ahead of competing brands?
Foradil: do reimbursement issues win or lose more share for Foradil?
Serevent: how much do guidelines and patient restrictions eat into Serevent's market share?
Spiriva: how much of Spiriva's share gain comes from competitors not being on formularies?
Symbicort: is the secret to Symbicort's impressive share gain due to cost or formulary availability?
Tudorza: could better formulary availability stem Tudorza's share loss?
Key Issues Explored
Market Access Impact in Asthma/COPD explores key issues affecting asthma/COPD drug makers. You'll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest effect?
How barriers affect your brand:
How many doctors prescribe your brand? How many don't, but would consider it?
Why don't doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
Market Access Impact in Asthma/COPD is based on a survey of 100 US physicians—56 pulmonologists and 44 general practitioners.
All respondents have:
Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 50 patients with asthma or COPD in total in the last month
Get Answers On The Following Brands
Advair (fluticasone/salmeterol; GlaxoSmithKline)
Arcapta (indacaterol; Novartis)
Foradil (formoterol; Novartis/Merck & Co.)
Serevent (salmeterol; GlaxoSmithKline)
Spiriva (tiotropium; Boehringer Ingelheim)
Symbicort (budesonide/formoterol; AstraZeneca)
Tudorza (aclidinium; AstraZeneca)
Add the EU5 report to your order and get a free comparison report
Also available, the Market Access Impact in Asthma/COPD—EU5 edition
Based on a survey of 100 physicians from the United States, the report reveals how market barriers affect the leading asthma/COPD brands in the US market.
Order the EU5 and US reports together and you'll receive a free companion report comparing results from both markets.
Email us for details or call +1 212-220-0880 or +44(0)20.7665.9240
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.
Read the full report: http://www.reportlinker.com/p03362821-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001